Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

DNA Repair Gene Alterations and PARP Inhibitor Response in Patients With Metastatic Castration-Resistant Prostate Cancer.

Journal of the National Comprehensive Cancer Network : JNCCN - 1 Aug 2018

Lu Eric, Thomas George V, Chen Yiyi, Wyatt Alexander W, Lloyd Paul, Youngren Jack, Quigley David, Bergan Raymond, Bailey Shawna, Beer Tomasz M, Feng Felix Y, Small Eric J, Alumkal Joshi J

Abstract excerpt

Background: PARP inhibition is a promising therapeutic strategy for the treatment of men with metastatic castration-resistant prostate cancer whose tumors harbor homologous recombination DNA repair gene alterations. However, questions remain for many practicing clinicians about which patients are ideally suited for PARP inhibitor treatment. This report details our institutional experience using PARP inhibitor...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to BRCA2 Protein

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to DNA Repair

Share to Drug Resistance, Neoplasm

Share to Poly(ADP-ribose) Polymerase Inhibitors

Share to Prognosis

Share to Prostatic Neoplasms, Castration-Resistant

Share to Treatment Outcome

Source

Identifiers

PMID: 30099369
DOI: 10.6004/jnccn.2018.7020

Genes

BRCA2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

DNA Repair Gene Alterations and PARP Inhibitor Response in Patients With Metastatic Castration-Resistant Prostate Cancer.PMID 30099369Read ↗

Impact of mutations in homologous recombination repair genes on treatment outcomes for metastatic castration resistant prostate cancer.Semantic proximity Read ↗

Treatment strategies for DNA repair-deficient prostate cancer.Semantic proximity Read ↗

Targeting DNA RepairSemantic proximity Read ↗

Genetic Aberrations of DNA Repair Pathways in Prostate Cancer: Translation to the ClinicSemantic proximity Read ↗

Alterations in BRCA2 as Determinants of Therapy Response in Prostate Cancer.Semantic proximity Read ↗

PARP Inhibitors and Prostate Cancer: To Infinity and BeyondBRCASemantic proximity Read ↗

TMPRSS2:ERGGene Fusion Might Predict Resistance to PARP Inhibitors in Metastatic Castration-resistant Prostate CancerSemantic proximity Read ↗

Targeting PARP in Prostate Cancer: Novelty, Pitfalls, and Promise.Semantic proximity Read ↗

Therapeutic targeting of the DNA damage response in prostate cancerSemantic proximity Read ↗

Homologous Recombination Repair Gene Mutations in Prostate Cancer: Prevalence and Clinical Value.Semantic proximity Read ↗

A panel-based mutational signature of homologous recombination deficiency associates with response to PARP inhibition in metastatic castration-resistant prostate cancer.Semantic proximity Read ↗

Identification of Novel Biomarkers of Homologous Recombination Defect in DNA Repair to Predict Sensitivity of Prostate Cancer Cells to PARP-InhibitorsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.